Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Bibliographic Details
Main Authors:	Diego Centonze, Sergio Iannazzo, Laura Santoni, Cecilia Saleri, Elisa Puma, Luigi Giuliani, Pier Luigi Canonico
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2018-11-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	cost-effectiveness peginterferon beta-1a multiple sclerosis
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1385

Similar Items

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

[Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management]
by: Sergio Iannazzo, et al.
Published: (2016-07-01)

Peginterferon beta-1a – nowa postać interferonu beta-1a
by: Zdzisław Maciejek, et al.
Published: (2015-11-01)

[Pegylation and interferons in multiple sclerosis]
by: Diego Centonze, et al.
Published: (2016-07-01)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
by: Annette Kolb-Mäurer, et al.
Published: (2019-06-01)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
by: Hendin B, et al.
Published: (2018-07-01)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
by: Young Kul Jung, et al.
Published: (2013-03-01)

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin
by: Alejandro Soza, M.D., et al.
Published: (2015-01-01)

EVALUATION OF HBV DNA LEVELS IN SALIVA IN SUBJECTS WITH DIFFERENT VIREMIA AS WELL AS DURING PEGINTERFERON α-2a THERAPY.
by: Assya Krasteva, et al.
Published: (2013-08-01)

[Pegylated interferon beta-1a on the Italian market]
by: Mario Eandi
Published: (2016-07-01)

Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al.

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
by: Suh Yoon Yang, et al.
Published: (2015-06-01)

Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs
by: Xuli Bao, et al.
Published: (2020-07-01)

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
by: Zhang Yu-guo, et al.
Published: (2011-06-01)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
by: Artico Simara, et al.
Published: (2012-12-01)

Peginterferon-alpha 2a related peripheral neuropathy: A case report and review of the literature
by: Amalia Ghergu, et al.
Published: (2017-09-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
by: Seok Hoo Jeong, et al.
Published: (2012-12-01)

Sexual dysfunction in males with hepatitis C virus: Relevance to histopathologic changes and peginterferon treatment
by: Kamal A El-Atrebi, et al.
Published: (2011-01-01)

Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
by: Sener Barut, et al.

Effect of Lyophilization on Stability of PEG-Protein Conjugate: A Case Study with Peginterferon alfa-2b
by: Patel Chintan, et al.
Published: (2023-04-01)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial
by: Mario G. Pessôa, et al.
Published: (2012-01-01)

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-06-01)

Results of peginterferon alpha-2a treatment in patients with chronic hepatitis B in the Western part of Romania
by: Roxana Șirli, et al.
Published: (2016-12-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022-10-01)

Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
by: Scott D. Newsome, et al.
Published: (2017-01-01)

An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
by: Pavan Bhargava, et al.
Published: (2016-11-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
by: Damiano Paolicelli, et al.
Published: (2016-01-01)

Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
by: I-Cheng Lee, et al.
Published: (2021-09-01)

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial
by: Francisco Bosques-Padilla, MD, et al.
Published: (2003-07-01)

by: Sergio lannazzo, et al.
Published: (2016-06-01)

A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. I. Yakushina, et al.
Published: (2016-07-01)

Combination of Novel Therapies for HDV
by: Menashe Elazar, et al.
Published: (2022-01-01)

Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report
by: Rebecca Maunsell, et al.
Published: (2017-09-01)

The Combination Therapy with Peg-interferon Alfa and Ribavirin for Chronic Hepatitis C in Korea as an Initial Treatment
by: Dong Hyun Park, et al.
Published: (2012-12-01)

Comparison Of The Expression Of MiR-326 Between Interferon Beta Responders And Non-Responders In Relapsing-Remitting Multiple Sclerosis
by: Mahtab Fattahi, et al.
Published: (2020-04-01)

Clinical evolution of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a
by: Lazaro Aurelio Vazquez-Gomez, et al.
Published: (2022-09-01)

Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study
by: Yunus Gürbüz, et al.
Published: (2016-02-01)

Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)
by: Diego Centonze, et al.
Published: (2021-04-01)